Both in Pharmaceuticals
Bicara Therapeutics vs DiaMedica Therapeutics
Over the past year BCAX returned −42.7% and DMAC returned +43.1%; their daily moves had a correlation of 0.06.
BCAX −42.7% DMAC +43.1%Growth of $1, one year, split-adjusted
| Metric | BCAX | DMAC |
|---|---|---|
| Price | $9.16 | $9.73 |
| Market cap | $606.1M | $524.7M |
| Today | +15.51% | +4.74% |
| 1 month | −47.0% | +15.6% |
| 6 months | −60.4% | +55.7% |
| Year to date | −45.6% | +22.2% |
| 1 year | −43.6% | +37.8% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $497.3M | $43.5M |
| Dividend yield | — | — |
| Volatility (60d) | 135.8% | 53.6% |
| Short % of float | 23.9% | 21.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).